argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
670.33
+71.44 (11.93%)
Jul 31, 2025, 4:00 PM - Market closed
CTI BioPharma Stock Forecast
Stock Price Forecast
The 15 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $734.67, which forecasts a 9.60% increase in the stock price over the next year. The lowest target is $605 and the highest is $1,065.
Price Target: $734.67 (+9.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 5 | 5 |
| Buy | 12 | 12 | 13 | 12 | 12 | 12 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 20 | 19 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $720 → $774 | Strong Buy | Maintains | $720 → $774 | +15.47% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $741 → $756 | Buy | Maintains | $741 → $756 | +12.78% | Jul 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $720 | Strong Buy | Reiterates | $720 | +7.41% | Jul 1, 2025 |
| Wedbush | Wedbush | Buy Reiterates $715 | Buy | Reiterates | $715 | +6.66% | Jun 24, 2025 |
| Wedbush | Wedbush | Buy Reiterates $715 | Buy | Reiterates | $715 | +6.66% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
3.70B
from 2.25B
Increased by 64.75%
Revenue Next Year
4.81B
from 3.70B
Increased by 29.81%
EPS This Year
11.71
from 12.78
Decreased by -8.40%
EPS Next Year
20.32
from 11.71
Increased by 73.57%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.4B | 6.2B | 8.8B | ||
| Avg | 3.7B | 4.8B | 6.0B | ||
| Low | 3.0B | 3.8B | 4.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.9% | 66.9% | 83.4% | ||
| Avg | 64.8% | 29.8% | 24.2% | ||
| Low | 34.6% | 3.1% | -1.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.32 | 32.75 | 52.95 | ||
| Avg | 11.71 | 20.32 | 28.77 | ||
| Low | 5.34 | 11.17 | 10.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 51.2% | 179.8% | 160.6% | ||
| Avg | -8.4% | 73.6% | 41.6% | ||
| Low | -58.2% | -4.6% | -46.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.